TapewireFind a company

person · Reporting owner

Ford David A

Disclosed activity across 2 companies

Tapewire entity
82231
SEC CIK
0001705295

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375Chief People OfficerMarch 05, 2025March 07, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PROTHENA CORP PUBLIC LTD CO

Report date March 05, 2025 · Filed March 07, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.95 · Expires 2035-03-05Direct107,500 Reported balance After 2025-03-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-03-05 · Grant · Acquired 107,500 · Balance 107,500

F1: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 5, 2026, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 5, 2026, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

INTERCEPT PHARMACEUTICALS, INC.

Report date November 08, 2023 · Filed November 13, 2023

Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2023-11-08 transaction · row 1 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 1 · 2023-11-08 · Other · Disposed 15,038 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2023-11-08 transaction · row 2 Sequence does not reconcile; account continuity is unresolved.
1 source row

Row 2 · 2023-11-08 · Disposition to issuer · Disposed 21,400 · Balance 0

F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $14.44Direct0 Reported balance After 2023-11-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2023-11-08 · Disposition to issuer · Disposed 11,300 · Balance 0

F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.40Direct0 Reported balance After 2023-11-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2023-11-08 · Disposition to issuer · Disposed 16,000 · Balance 0

F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $114.90Direct0 Reported balance After 2023-11-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2023-11-08 · Disposition to issuer · Disposed 3,480 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $114.90Direct0 Reported balance After 2023-11-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2023-11-08 · Disposition to issuer · Disposed 8,520 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $58.74Direct0 Reported balance After 2023-11-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2023-11-08 · Disposition to issuer · Disposed 6,463 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $58.74Direct0 Reported balance After 2023-11-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2023-11-08 · Disposition to issuer · Disposed 3 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $110.80Direct0 Reported balance After 2023-11-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2023-11-08 · Disposition to issuer · Disposed 900 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $110.80Direct0 Reported balance After 2023-11-08 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2023-11-08 · Disposition to issuer · Disposed 5,200 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $99.66Direct0 Reported balance After 2023-11-08 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2023-11-08 · Disposition to issuer · Disposed 5,900 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $29.46Direct0 Reported balance After 2023-11-08 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2023-11-08 · Disposition to issuer · Disposed 18,000 · Balance 0

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.

F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 05, 2025 Filed Mar 7, 2025 21:24 UTC PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 GrantStock Option (Right to Buy) · Derivative 107,500 $0.00 Strike: $14.95 $0.00
Disclosure

SEC source: 0000905148-25-000881 · form4.xml · derivative · entry 1

Ford David A · CIK 0001705295 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,500

Underlying: Ordinary Shares · 107,500 shares

Expires 2035-03-05

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 5, 2026, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 02:03 UTC PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 GrantStock Option (Right to Buy) · Derivative 85,000 $0.00 Strike: $28.53 $0.00
Disclosure

SEC source: 0000905148-24-000889 · form4.xml · derivative · entry 1

Ford David A · CIK 0001705295 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Ordinary Shares · 85,000 shares

Expires 2034-03-01

F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 1, 2025 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:42 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 18,000 Not disclosed Strike: $29.46 Not disclosed
Disclosure

SEC source: 0001104659-23-117100 · tm2330435-3_4seq1.xml · derivative · entry 12

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,000 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:42 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 5,900 Not disclosed Strike: $99.66 Not disclosed
Disclosure

SEC source: 0001104659-23-117100 · tm2330435-3_4seq1.xml · derivative · entry 11

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,900 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:42 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 5,200 Not disclosed Strike: $110.80 Not disclosed
Disclosure

SEC source: 0001104659-23-117100 · tm2330435-3_4seq1.xml · derivative · entry 10

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,200 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:42 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 900 Not disclosed Strike: $110.80 Not disclosed
Disclosure

SEC source: 0001104659-23-117100 · tm2330435-3_4seq1.xml · derivative · entry 9

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 900 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:42 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 3 Not disclosed Strike: $58.74 Not disclosed
Disclosure

SEC source: 0001104659-23-117100 · tm2330435-3_4seq1.xml · derivative · entry 8

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:42 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 6,463 Not disclosed Strike: $58.74 Not disclosed
Disclosure

SEC source: 0001104659-23-117100 · tm2330435-3_4seq1.xml · derivative · entry 7

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,463 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:42 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 8,520 Not disclosed Strike: $114.90 Not disclosed
Disclosure

SEC source: 0001104659-23-117100 · tm2330435-3_4seq1.xml · derivative · entry 6

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,520 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:42 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 3,480 Not disclosed Strike: $114.90 Not disclosed
Disclosure

SEC source: 0001104659-23-117100 · tm2330435-3_4seq1.xml · derivative · entry 5

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,480 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:42 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 16,000 Not disclosed Strike: $18.40 Not disclosed
Disclosure

SEC source: 0001104659-23-117100 · tm2330435-3_4seq1.xml · derivative · entry 4

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,000 shares

Expires not disclosed

F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:42 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerOption to Purchase Common Stock · Derivative 11,300 Not disclosed Strike: $14.44 Not disclosed
Disclosure

SEC source: 0001104659-23-117100 · tm2330435-3_4seq1.xml · derivative · entry 3

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,300 shares

Expires not disclosed

F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:42 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Disposition to issuerCommon Stock 21,400 $19.00 $406,600.00
Disclosure

SEC source: 0001104659-23-117100 · tm2330435-3_4seq1.xml · nonDerivative · entry 2

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 14:42 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 OtherCommon Stock 15,038 $19.00 $285,722.00
Disclosure

SEC source: 0001104659-23-117100 · tm2330435-3_4seq1.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

Read SEC document
January 27, 2023 Filed Jan 31, 2023 16:04 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantOption to Purchase Common Stock · Derivative 16,000 $0.00 Strike: $18.40 $0.00
Disclosure

SEC source: 0001104659-23-008584 · tm234878-3_4seq1.xml · derivative · entry 2

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2033-01-27

F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2023.

Read SEC document
January 27, 2023 Filed Jan 31, 2023 16:04 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 9,800 $0.00 $0.00
Disclosure

SEC source: 0001104659-23-008584 · tm234878-3_4seq1.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,438

F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2023.

Read SEC document
December 31, 2022 Filed Jan 3, 2023 16:02 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 1,777 $12.37 $21,981.49
Disclosure

SEC source: 0001104659-23-000330 · tm231319-3_4seq1.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,638

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person.

Read SEC document
January 27, 2022 Filed Jan 31, 2022 16:14 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantOption to Purchase Common Stock · Derivative 11,300 $0.00 Strike: $14.44 $0.00
Disclosure

SEC source: 0001104659-22-009558 · tm224882-5_4seq1.xml · derivative · entry 2

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,300

Underlying: Common Stock · 11,300 shares

Expires 2032-01-27

F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2022.

Read SEC document
January 27, 2022 Filed Jan 31, 2022 16:14 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 6,600 $0.00 $0.00
Disclosure

SEC source: 0001104659-22-009558 · tm224882-5_4seq1.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,415

F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2022.

Read SEC document
January 01, 2022 Filed Jan 4, 2022 16:17 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 106 $16.29 $1,726.74
Disclosure

SEC source: 0001104659-22-000923 · tm221409d3_4.xml · nonDerivative · entry 2

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,815

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person.

Read SEC document
December 31, 2021 Filed Jan 4, 2022 16:17 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 1,606 $16.29 $26,161.74
Disclosure

SEC source: 0001104659-22-000923 · tm221409d3_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,921

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person.

Read SEC document
October 01, 2021 Filed Oct 5, 2021 17:28 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 92 $15.22 $1,400.24
Disclosure

SEC source: 0001104659-21-123210 · tm2129255d2_4seq1.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,527

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
July 01, 2021 Filed Jul 2, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 92 $20.47 $1,883.24
Disclosure

SEC source: 0001104659-21-089032 · tm2121399-2_4seq1.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,619

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
May 08, 2021 Filed May 11, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 128 $17.15 $2,195.20
Disclosure

SEC source: 0001104659-21-064695 · tm2115919-1_4seq1.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,711

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
April 01, 2021 Filed Apr 5, 2021 19:02 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 92 $24.28 $2,233.76
Disclosure

SEC source: 0001104659-21-046700 · tm2111402-4_4seq1.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,839

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 148 $36.04 $5,333.92
Disclosure

SEC source: 0001104659-21-020007 · tm215983d1_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,931

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
January 22, 2021 Filed Jan 26, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantOption to Purchase Common Stock · Derivative 18,000 $0.00 Strike: $29.46 $0.00
Disclosure

SEC source: 0001104659-21-007780 · tm214232d4_4.xml · derivative · entry 2

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2031-01-22

F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2021.

Read SEC document
January 22, 2021 Filed Jan 26, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 11,500 $0.00 $0.00
Disclosure

SEC source: 0001104659-21-007780 · tm214232d4_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,079

F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2021.

Read SEC document
January 01, 2021 Filed Jan 5, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 106 $24.70 $2,618.20
Disclosure

SEC source: 0001104659-21-001122 · tm211606-4_4seq1.xml · nonDerivative · entry 2

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,579

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person.

Read SEC document
December 31, 2020 Filed Jan 5, 2021 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 629 $24.70 $15,536.30
Disclosure

SEC source: 0001104659-21-001122 · tm211606-4_4seq1.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,685

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person.

Read SEC document
November 08, 2020 Filed Nov 10, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 128 $28.15 $3,603.20
Disclosure

SEC source: 0001104659-20-123704 · tm2035590d1_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,314

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 92 $42.08 $3,871.36
Disclosure

SEC source: 0001104659-20-112316 · tm2032461d1_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,442

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
August 08, 2020 Filed Aug 11, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 128 $48.75 $6,240.00
Disclosure

SEC source: 0001104659-20-093397 · tm2027122d1_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,534

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
July 01, 2020 Filed Jul 6, 2020 19:01 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 92 $46.52 $4,279.84
Disclosure

SEC source: 0001104659-20-081435 · tm2024073d4_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,662

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
May 08, 2020 Filed May 12, 2020 19:02 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 128 $87.80 $11,238.40
Disclosure

SEC source: 0001104659-20-060294 · tm2019428d1_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,754

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
April 09, 2020 Filed Apr 10, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 SaleCommon Stock 58 $70.00 $4,060.00
Disclosure

SEC source: 0001104659-20-045621 · tm2015640d1_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,882

F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.

Read SEC document
April 01, 2020 Filed Apr 3, 2020 19:02 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 92 $58.40 $5,372.80
Disclosure

SEC source: 0001104659-20-043286 · tm2014981d4_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,940

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
February 08, 2020 Filed Feb 11, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 148 $95.17 $14,085.16
Disclosure

SEC source: 0001104659-20-016893 · tm207520d1_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,032

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
January 23, 2020 Filed Jan 27, 2020 19:05 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantOption to Purchase Common Stock · Derivative 5,900 $0.00 Strike: $99.66 $0.00
Disclosure

SEC source: 0001104659-20-007265 · tm205922d6_4.xml · derivative · entry 2

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,900

Underlying: Common Stock · 5,900 shares

Expires 2030-01-23

F2 · derivative.exercise_date: The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020.

Read SEC document
January 23, 2020 Filed Jan 27, 2020 19:05 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 GrantCommon Stock 3,600 $0.00 $0.00
Disclosure

SEC source: 0001104659-20-007265 · tm205922d6_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,180

F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020.

Read SEC document
January 01, 2020 Filed Jan 3, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 106 $123.92 $13,135.52
Disclosure

SEC source: 0001104659-20-001085 · tm201209d2_4.xml · nonDerivative · entry 2

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,839

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
December 31, 2019 Filed Jan 3, 2020 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 323 $123.92 $40,026.16
Disclosure

SEC source: 0001104659-20-001085 · tm201209d2_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,945

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
November 08, 2019 Filed Nov 12, 2019 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 128 $82.76 $10,593.28
Disclosure

SEC source: 0001104659-19-062781 · tm1922493d1_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,268

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
October 23, 2019 Filed Oct 25, 2019 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 SaleCommon Stock 58 $70.00 $4,060.00
Disclosure

SEC source: 0001104659-19-056609 · tm1920920d1_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,396

F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.

Read SEC document
October 01, 2019 Filed Oct 3, 2019 19:04 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 92 $65.87 $6,060.04
Disclosure

SEC source: 0001144204-19-047225 · tv530565_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,454

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
September 16, 2019 Filed Sep 18, 2019 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 SaleCommon Stock 800 $70.00 $56,000.00
Disclosure

SEC source: 0001144204-19-045112 · tv529591_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,546

F1 · kind: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.

Read SEC document
August 08, 2019 Filed Aug 9, 2019 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 128 $66.05 $8,454.40
Disclosure

SEC source: 0001144204-19-038975 · tv527281_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,346

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
July 01, 2019 Filed Jul 3, 2019 17:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 92 $79.17 $7,283.64
Disclosure

SEC source: 0001144204-19-033815 · tv524734_form4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,474

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document
May 08, 2019 Filed May 10, 2019 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 128 $87.57 $11,208.96
Disclosure

SEC source: 0001144204-19-025390 · tv521144_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,566

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.

Read SEC document
April 01, 2019 Filed Apr 3, 2019 19:00 UTC INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 Tax withholdingCommon Stock 92 $111.50 $10,258.00
Disclosure

SEC source: 0001144204-19-018078 · tv517924_4.xml · nonDerivative · entry 1

Ford David A · CIK 0001705295 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,694

F1 · shares: Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.